Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This article reviews real-world data supporting homologous recombination deficiency (HRD) testing in BRCA1/2 wild-type high-grade serous carcinoma and examines MYC amplification as a promising surrogate biomarker to guide PARP inhibitor the
This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of s
In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.
A Phase Ib study of sapacitabine and olaparib in gBRCA-mutated metastatic breast cancer showed a 50% objective response rate and 9.7-month median PFS. While significant hematological toxicities limited dose escalation, the combination demon
The AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improves progression-free survival in HRR-deficient metastatic prostate cancer, with maintained quality of life and manageable safet
Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment ac
Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…